Table 1.
Randomized comparative studies investigating bevacizumab in ovarian cancer
| Study | Phase | Indication | Treatment | N | Median PFS, months | PFS HR (95% CI) | Median OS, months | OS HR (95% CI) | ORR (%) | P value for ORR |
|---|---|---|---|---|---|---|---|---|---|---|
| ICON7 [71, 72] | III | First line | Bevacizumab + CT | 764 | 19.9 |
0.93 (0.83–1.05) P = 0.25 |
58.0 |
0.99 (0.85–1.14) P = 0.85 |
67 | < 0.001 |
| CT | 764 | 17.5 | 58.6 | 48 | ||||||
| GOG0218 [68] | III | First line | Bevacizumab + CT | 623 | 14.1 |
0.72 (0.63–0.82) P < 0.001 |
39.7 |
0.92 (0.73–1.15) P = 0.45 |
NA | NA |
| CT | 625 | 10.3 | 39.3 | |||||||
| OCEANS [66, 67] | III | Recurrent, Plat-sens | Bevacizumab + CT | 242 | 12.4 |
0.48 (0.39–0.61) P < 0.0001 |
33.6 |
0.95 (0.77–1.18) P = 0.65 |
78.5 | < 0.0001 |
| CT | 242 | 8.4 | 32.9 | 57.4 | ||||||
| GOG0213 [69, 70] | III | Recurrent, Plat-sens | Bevacizumab + CT | 337 | 13.8 |
0.63 (0.53–0.74) P < 0.0001 |
42.2 |
0.83 (0.68–1.01) P = 0.056 |
78 | < 0.0001 |
| CT | 337 | 10.4 | 37.3 | 59 | ||||||
| MITO-168 [73] | III | Recurrent, Plat sensa | Bevacizumab + CT | 405 | 11.8 |
0.51 (0.41–0.64) P < 0.001 |
26.7 |
1.00 (0.73–1.39) P = 0.98 |
NA | NA |
| CT | 8.8 | 27.1 | NA | |||||||
| AURELIA [74] | III | Recurrent, Plat resist | Bevacizumab + CT | 179 | 6.7 |
0.48 (0.38–0.60) P < 0.001 |
16.6 |
0.85 (0.66–1.08) P < 0.174 |
30.9 | < 0.001 |
| CT | 182 | 3.4 | 13.3 | 12.6 |
aAfter first-line bevacizumab. CI confidence intervals; CT chemotherapy; HR hazard ratio; NA not available; NR not reached; PEG-Lipo pegylated liposomal; OS overall survival; PFS progression-free survival; Plat platinum; Resist resistant; Sens sensitive